Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants

AIDS Research and Human Retroviruses

Volumn 25, Issue 8, 2009, Pages 811-817

  Garg, Himanshu ^a   Joshi, Anjali ^a   Blumenthal, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL RESISTANCE; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CD4 LYMPHOCYTE COUNT; CELL FUSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS PATHOGENESIS; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS;

EID: 70349204182     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0010     Document Type: Article

References (33)

1. Gougeon ML and Montagnier L: Apoptosis in AIDS. Science 1993;260(5112):1269-1270.
2. Ahr B, Robert-Hebmann V, Devaux C, and Biard-Piechaczyk M: Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 2004;1(1):12.
3. Perfettini JL, Castedo M, Roumier T, et al.: Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ 2005;12(Suppl 1):916-923.
4. Blanco J, Barretina J, Ferri KF, et al.: Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41mediated hemifusion-like events. Virology 2003;305(2):318-329.
5. Garg H, Joshi A, Freed EO, and Blumenthal R: Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV- 1-mediated bystander apoptosis and fusion=hemifusion. J Biol Chem 2007;282(23):16899-16906.
6. Olivieri K, Scoggins RM, Bor YC, et al.: The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. Virology 2007;358(1):23-38.
7. Blanco J, Barretina J, Clotet B, and Este JA: R5 HIV gp120mediated cellular contacts induce the death of single CCR5expressing CD4 T cells by a gp41-dependent mechanism. J Leukoc Biol 2004;76(4):804-811.
8. Garg H and Blumenthal R: Role of HIV Gp41 mediated fusion=hemifusion in bystander apoptosis. Cell Mol Life Sci 2008;65(20):3134-3144.
9. Stocker H, Scheller C, and Jassoy C: Destruction of primary CD4(p) T cells by cell-cell interaction in human immunodeficiency virus type 1 infection in vitro. J Gen Virol 2000;81(Pt 8):1907-1911.
10. Gallo SA, Finnegan CM, Viard M, et al.: The HIV Envmediated fusion reaction. Biochim Biophys Acta 2003; 1614(1):36-50.
11. Wild C, Dubay JW, Greenwell T, et al.: Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994;91(26):12676-12680.
12. Wild CT, Shugars DC, Greenwell TK, McDanal CB, and Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91(21):9770-9774.
13. Saberi P, Caswell NH, Gruta CI, Tokumoto JN, and Dong BJ: Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program. Ann Pharmacother 2008;42(5):621-626.
14. Barretina J, Blanco J, Armand-Ugon M, et al.: Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir Ther 2003;8(2):155-161.
15. Garg H and Blumenthal R: HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 2006;79(2):351-362.
16. Barretina J, Blanco J, Bonjoch A, et al.: Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004;18(12):1673-1682.
17. Aquaro S, D'Arrigo R, Svicher V, et al.: specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58(4):714-722.
18. Melby TE, Despirito M, Demasi RA, et al.: Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007;21(18): 2537-2539.
19. Svicher V, Aquaro S, D'Arrigo R, et al.: specific enfuvirtideassociated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(P) cell count, despite virological failure. J Infect Dis 2008;197(10):1408-1418.
20. Melby T, Sista P, Demasi R, et al.: Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22(5):375-385.
21. Mink M, Mosier SM, Janumpalli S, et al.: Impact of human immunodeficiency virus type 1 gp41 amino acid substitu tions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005; 79(19):12447-12454.
22. Reeves JD, Lee FH, Miamidian JL, et al.: Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005;79(8):4991-4999.
23. Chinnadurai R, Rajan D, Munch J, and Kirchhoff F: Human immunodeficiency virus type 1 variants resistant to first-and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol 2007;81(12):6563-6572.
24. Descamps D, Assoumou L, Masquelier B, et al.: HIV-1infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. J Antimicrob Chemother 2008;62(3):451-455.
25. Trabaud MA, Cotte L, Labernardiere JL, et al.: Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo. J Acquir Immune Defic Syndr 2007; 46(2):134-144.
26. Labrosse B, Labernardiere JL, Dam E, et al.: Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003;77(2):1610-1613.
27. Xu L, Pozniak A, Wildfire A, et al.: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49(3):1113-1119.
28. Labrosse B, Morand-Joubert L, Goubard A, et al.: Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006;80(17):8807-8819.
29. Derdeyn CA, Decker JM, Sfakianos JN, et al.: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74(18):8358-8367.
30. Meissner EG, Coffield VM, and Su L: Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1=V2-associated CD4 binding efficiency and viral entry. Virology 2005;336(2):184-197.
31. Yang X, Kurteva S, Ren X, Lee S, and Sodroski J: Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 2005;79(19): 12132-12147. (Pubitemid 41348726)
32. Cao J, Vasir B, and Sodroski JG. Changes in the cytopathic effects of human immunodeficiency virus type 1 associated with a single amino acid alteration in the ectodomain of the gp41 transmembrane glycoprotein. J Virol 1994;68(7):4662-4668.
33. Eggink D, Baldwin CE, Deng Y, et al.: Selection of T1249resistant human immunodeficiency virus type 1 variants. J Virol 2008;82(13):6678-6688.